23 results about "Immunologic diseases" patented technology

The present invention relates to the field of cell therapy. Disclosed are a fibroblast activation protein-targeting CAR T-cell, a preparation method therefor, and an application thereof. A CAR T-cell can be prepared by introducing an FAP-targeting chimeric antigen receptor (CAR) into a T lymphocyte, wherein the CAR in the CAR T-cell comprises a signal peptide, an antigen-binding domain, a hinge region, a transmembrane domain, a co-stimulatory signaling region, and a CD3 signaling domain. The CAR T-cell specifically recognizes the FAP by means of a single-chain variable fragment (scFv), which activates an intracellular signaling pathway, releasing cytokine IFN-γ, and exhibiting a cytotoxic effect on FAP+ cells, thereby achieving specific depletion of FAP+ cells at a lesion site. The CAR-T cell can be used for treating diseases characterized by upregulated FAP expression, such as fibrosis (pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, renal fibrosis, etc.), arthritis, autoimmune disorders (Crohn's disease, rheumatoid arthritis, etc.), and cardiovascular diseases, and demonstrates tremendous application potential and commercial value.

The present application relates to a BDCA2-binding protein and a pharmaceutical use thereof. Specifically, the present application relates to a BDCA2-binding protein and a pharmaceutical use thereof in treating autoimmune diseases.

Disclosed herein is are methods of preventing, reducing or inhibiting a viral or immune disorder, comprising administering to a subject at risk or that has acquired a viral or immune disorder an effective amount of a composition comprising a polypeptide derived from a reactive center loop of a serine protease inhibitor or a biologically active variant thereof, wherein the subject has not been administered antibiotics within at least one day of administering the composition. Also disclosed are compositions and kits for preventing, reducing or inhibiting a viral or immune disorder.

This invention relates to APRIL and BAFF inhibitory immunomodulatory proteins and methods of using them, specifically providing immunomodulatory proteins exhibiting neutralizing activity against BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of transmembrane activators and CAML interactors (TACI). The provided immunomodulatory proteins include TACI-Fc fusion proteins. Nucleic acid molecules encoding said immunomodulatory proteins are also provided. The immunomodulatory proteins provide therapeutic efficacy against a variety of immune diseases, disorders, or conditions. Compositions and methods for preparing and using such proteins are also provided.

This invention discloses compounds of formula I, wherein X1, X2, and R 1 and R 2 As defined herein, this invention relates to compounds for the prevention and / or treatment of the following diseases, methods of their preparation, pharmaceutical compositions comprising them, and methods of treatment using them: inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases involving impaired cartilage turnover, congenital cartilage malformations, diseases involving impaired bone turnover, diseases associated with excessive IL-6 secretion, diseases associated with excessive secretion of TNFα, interferon, IL-12, IL-17, and / or IL-23, respiratory diseases, endocrine diseases, metabolic diseases, cardiovascular diseases, skin diseases, and / or diseases associated with abnormal angiogenesis, wherein the methods are carried out by administering the compounds of the invention.

The present invention discloses an anti-BDCA2 antibody and its antigen-binding fragment, a polynucleotide encoding the antibody and its antigen-binding fragment, and a pharmaceutical composition comprising the antibody and its antigen-binding fragment. Furthermore, the use of the anti-BDCA2 antibody and its antigen-binding fragment described in the present invention in the treatment of plasmacytoid dendritic cell (pDC) or type I interferon (type I IFN)-associated immune diseases is also disclosed.

This disclosure relates to an imidazole lipid and its applications. Specifically, it provides a compound as shown in Formula I or a salt thereof, as well as lipid particles or pharmaceutical compositions containing the same. The compound can be used as a delivery system for the preparation of medicaments for the prevention and / or treatment of cancer, infectious diseases, autoimmune diseases, neurodegenerative diseases, and inflammation, etc. The definitions of the various groups in Formula (I) are as described in the specification.

A novel use of a drug for intervention in an IPMK target. It is found for the first time that HIF2α and GATA3 jointly regulate IPMK and a PI3K-AKT signaling pathway to mediate pathogenic Th2 cell differentiation, and it is verified for the first time that intervention in the IPMK target enables prevention and treatment of type II immune diseases and diseases caused by dysregulated Th2 / ILC2 differentiation and acts against tumors, aging and aging related diseases, thereby providing a new potential target for clinical treatment of type II immune diseases, tumors, diseases caused by dysregulated Th2 / ILC2 differentiation, and aging and aging related diseases, and achieving good prospects for application.

This invention discloses a thiadiazolidinone compound with PTPN2 / PTPN1 inhibitory activity, its preparation method, and its applications, belonging to the field of medicinal chemistry. The thiadiazolidinone derivative described in this invention is a compound with the structure shown in general formula (I) or a pharmaceutically acceptable salt thereof. This invention also discloses the application of the above-mentioned thiadiazolidinone derivative in drugs for treating PTPN2 / PTPN1-mediated diseases. The compound disclosed in this invention has significant inhibitory activity against PTPN2 / PTPN1 phosphatases, and has an important influence on tumor development and immune response. It can also be used in combination with immunosuppressants to treat related immune diseases. It can be developed into an antitumor drug with high activity, good selectivity, and low toxicity, and has the characteristics of high plasticity and great potential for future modification.

This article describes heterobifunctional small molecules, methods of preparation, pharmaceutical compositions and pharmaceuticals comprising such heterobifunctional small molecules, and methods of using such heterobifunctional small molecules in the treatment of diseases and conditions such as cancer, autoimmune diseases and inflammatory diseases.

The present invention relates to compounds of formula (I) salts and derivatives thereof. Further object of the present invention are compositions, which comprise at least a compound of formula (I) or its pharmaceutically acceptable salts and derivatives, and at least one excipient. Further object of the present invention are compounds of formula (I) or compositions which comprise them, for use in the treatment or prevention of a cancer and / or a metabolic disease and / or an immunological disease. Further object of the present invention is the in vitro use of the compounds as chemical probes.

The present disclosure provides methods of treating subjects having an immune disorder by administering a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor to the subject, and optionally an Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) agonist or inhibitor and / or an HLA-Aw19 inhibitor, and also provides methods of identifying subjects having an increased risk for developing an MHC-I-opathy.

Heterobifunctional small molecules, methods of making, pharmaceutical compositions and medicaments comprising such heterobifunctional small molecules are described herein, and methods of using such heterobifunctional small molecules in the treatment of diseases and conditions, such as cancer, autoimmune diseases, and inflammatory diseases are described herein.

The application discloses a LAG-3 binding molecule, which comprises a LAG-3 antibody, or an antigen binding fragment of the LAG-3 antibody, or a fusion protein containing the LAG-3 antibody, or a fusion protein containing the antigen binding fragment, or an antibody drug conjugate containing the LAG-3 antibody, or an antibody drug conjugate containing the antigen binding fragment, or a bispecific antibody containing the LAG-3 antibody or a bispecific antibody containing the antigen binding fragment. The LAG-3 binding molecule provided by the application can bind to human and monkey LAG-3, has high affinity to human LAG-3, effectively enhances T cell response, can be used for regulating T cell and antibody-mediated immune response, and has wide therapeutic uses as an immunomodulator, such as cancer, autoimmune diseases, inflammatory diseases, and infectious diseases.

The application relates to, among others, self-stabilizing bridged ring connecting units and their application in antibody-drug conjugates, linker-drug compounds prepared by incorporating said linkers, and ligand-drug conjugates with stable quality and excellent homogeneity. The application also discloses methods for the preparation the linkers, linker-drug compounds, and ligand-drug conjugates, as well as the application of the linker -drug compounds, and ligand-drug conjugates in the treatment of tumors, infections, and immune diseases.

The present invention relates to an isolated muropeptide of formula (I) GlcNAc-MurNAc-X1-Glu-mDAP-(Ala)Y1-(X2)Y2 as well as peptidoglycans (PG) comprising it and to a composition comprising at least one muropeptide and / or at least one PG and to the implementation of the muropeptide, peptidoglycan or composition in the prevention and / or treatment, in an individual in need thereof, of an immune disorder selected from the group consisting of an inflammatory disorder, graft-versus-host disease (GVHD) and graft rejection; or of an infection; or of a metabolic disorder or of a cancer.

Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.

The present application provides anti-IL-13 antibodies and antigen binding fragments thereof. Such antibodies and antigen binding fragments thereof may be used in methods for the treatment and / or prevention of an immunological disease or disorder.

This invention relates to the field of medical management system technology, specifically disclosing a prognostic management system for patients with autoimmune diseases. It adopts an edge-cloud collaborative architecture, comprising a multimodal edge data acquisition and preprocessing module, an edge-end real-time status monitoring module, a cloud-based progressive prognostic assessment module, an intervention intensity matching and adverse reaction early warning module, an intervention effect closed-loop correction and federated learning module, and a doctor-patient shared decision-making and data feedback module, all connected sequentially. This invention simultaneously collects multi-dimensional patient data, achieving a comprehensive understanding of the patient's condition. Simultaneously, it performs preliminary data quality control and real-time status monitoring at the edge, reducing the computational burden on the cloud and enabling timely identification of sudden abnormalities in the patient's condition and triggering local early warnings. By calculating the effective contribution coefficients of each modality of data, the impact of different data on prognosis can be dynamically assessed, improving the effectiveness of data utilization.

This invention discloses a compound with a pyrrolopyridine structure, its preparation method, and its pharmaceutical uses. This invention provides a novel compound with a pyrrolopyridine structure and a method for synthesizing this series of compounds. Activity studies show that the compound with the pyrrolopyridine structure possesses excellent JAK protein kinase inhibitory activity. Those skilled in the art know that JAK protein kinase plays an important role in the occurrence and development of various diseases, such as various immune diseases, myeloproliferative disorders, and central nervous system inflammatory diseases; inhibiting JAK can treat or alleviate these diseases. Therefore, the compound with the pyrrolopyridine structure provided by this invention has the potential for development into a JAK inhibitor drug and for treating or alleviating diseases by inhibiting JAK.

The present application relates to a kind of metabolic enhancement type immune cell preparation in the application of the drug for treating autoimmune diseases, the protein expressed by the metabolic enhancement type immune cell includes the CAR of antigen recognition domain and interleukin-10.In the present application, the immune cell expression includes the CAR of antigen recognition domain and interleukin-10, can significantly improve the immune regulation of this immune cell, alleviate immune cell exhaustion, improve the activity of immune cell and the killing effect to target cell.The immune cell can also express the antibody of anti-IFN gamma or anti-IFNAR1 simultaneously, reduce the side effect of treatment, improve the safety and curative effect of autoimmune disease treatment.

The present invention relates to various antigen-binding domains and platforms for constructing conventional and next-generation chimeric antigen receptors for adoptive cell therapies for cancer, infections, allergic, degenerative, and immune disorders. Approaches for the activation and expansion of immune T cells for adoptive cell therapies for cancer, infections, allergic, degenerative, and immune disorders are also provided.

The present application relates to the technical field of medicine, and particularly discloses application of chiral hydroxychloroquine or a pharmaceutically acceptable salt thereof in preparation of a drug for preventing and treating immune diseases. The chiral hydroxychloroquine or the pharmaceutically acceptable salt thereof has a better inhibition rate and a lower cell survival rate on pathological cell proliferation caused by immune diseases, including but not limited to fibroblast-like synoviocytes; the chiral hydroxychloroquine or the salt thereof combined with methotrexate / ilaris (including but not limited to) can reduce the toxic side effects on normal cells and the cell survival rate, and has a better treatment effect on immune diseases.